or Try an Advanced Search...

    Technical Analysis for STTK - Shattuck Labs, Inc.

    Grade Last Price % Change Price Change
    F 1.11 -2.63% -0.03
    STTK closed down 2.63 percent on Wednesday, November 20, 2024, on 23 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical STTK trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness -2.63%
    Stochastic Reached Oversold Weakness -2.63%
    Lower Bollinger Band Touch Weakness -2.63%
    Oversold Stochastic Weakness -2.63%
    20 DMA Resistance Bearish 0.45%
    New 52 Week Closing Low Bearish 0.45%
    Older End-of-Day Signals for STTK ...

       Recent Intraday Alerts

    Alert Time
    Outside Day about 17 hours ago
    Fell Below Lower Bollinger Band about 17 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    Down 3% about 20 hours ago
    Lower Bollinger Band Support about 20 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    STTK Chart by TradingView
    Basic chart:

    Profile

    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Life Sciences Solid Tumors Autoimmune Disease Treatment Of Cancer Lymphoma Clinical Research Clinical Trial Ovarian Cancer Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer

    Is STTK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 16 Shattuck Labs Third Quarter 2024 Earnings: Beats Expectations
    Nov 15 Shattuck Labs sees cash runway into 2027
    Nov 14 Shattuck Labs GAAP EPS of -$0.33 beats by $0.06, revenue of $3M
    Nov 14 Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
    Oct 24 Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround
    Oct 8 After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
    Oct 2 Top Midday Decliners
    Oct 2 Shattuck Labs stock craters following pipeline and job cuts
    Oct 2 Shattuck cut to Neutral at Citi on program exit
    Oct 2 STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
    See more STTK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.76
    52 Week Low 1.07
    Average Volume 726,877
    200-Day Moving Average 5.64
    50-Day Moving Average 1.93
    20-Day Moving Average 1.24
    10-Day Moving Average 1.20
    Average True Range 0.15
    RSI (14) 35.06
    ADX 34.54
    +DI 19.26
    -DI 25.25
    Chandelier Exit (Long, 3 ATRs) 1.11
    Chandelier Exit (Short, 3 ATRs) 1.54
    Upper Bollinger Bands 1.39
    Lower Bollinger Band 1.09
    Percent B (%b) 0.08
    BandWidth 24.32
    MACD Line -0.18
    MACD Signal Line -0.22
    MACD Histogram 0.0422
    Fundamentals Value
    Market Cap 52.32 Million
    Num Shares 47.1 Million
    EPS -2.24
    Price-to-Earnings (P/E) Ratio -0.50
    Price-to-Sales 323.03
    Price-to-Book 3.76
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.27
    Resistance 3 (R3) 1.28 1.23 1.24
    Resistance 2 (R2) 1.23 1.19 1.23 1.23
    Resistance 1 (R1) 1.17 1.17 1.15 1.16 1.22
    Pivot Point 1.13 1.13 1.12 1.12 1.13
    Support 1 (S1) 1.07 1.09 1.05 1.06 1.00
    Support 2 (S2) 1.02 1.06 1.02 0.99
    Support 3 (S3) 0.96 1.02 0.98
    Support 4 (S4) 0.95